

# Christoph Correll

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/344910/christoph-correll-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

559  
papers

31,350  
citations

94  
h-index

160  
g-index

610  
ext. papers

39,309  
ext. citations

5.8  
avg, IF

7.69  
L-index

#	Paper	IF	Citations
559	The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach.. <i>BMC Psychiatry</i> , <b>2022</b> , 22, 32	4.2	1
558	Risk factors of postpartum depression and depressive symptoms: umbrella review of current evidence from systematic reviews and meta-analyses of observational studies.. <i>British Journal of Psychiatry</i> , <b>2022</b> , 1-12	5.4	3
557	Early Antipsychotic Non-response as a Predictor of Non-response and Non-remission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial.. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2022</b> ,	7.2	1
556	Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis.. <i>Schizophrenia Research</i> , <b>2022</b> , 240, 205-213	3.6	1
555	Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice.. <i>Pharmacopsychiatry</i> , <b>2022</b> ,	2	4
554	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe.. <i>Neuropsychiatric Disease and Treatment</i> , <b>2022</b> , 18, 201-219	3.1	1
553	Lifetime prevalence and clinical correlates of nonsuicidal self-injury in youth inpatients with eating disorders: a retrospective chart review.. <i>Child and Adolescent Psychiatry and Mental Health</i> , <b>2022</b> , 16, 17	6.8	1
552	Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics.. <i>NPJ Schizophrenia</i> , <b>2022</b> , 8, 5	5.5	4
551	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.. <i>Lancet Psychiatry</i> , <b>2022</b> , 9, 291-306	23.3	2
550	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends.. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2022</b> , 136, 104608	9	5
549	Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder.. <i>Comprehensive Psychiatry</i> , <b>2022</b> , 115, 152301	7.3	1
548	Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia.. <i>European Psychiatry</i> , <b>2022</b> , 1-35	6	1
547	Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis.. <i>PLoS Medicine</i> , <b>2022</b> , 19, e1003960	11.6	5
546	Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 795866	5	
545	Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors.. <i>World Psychiatry</i> , <b>2022</b> , 21, 248-271	14.4	8
544	Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.. <i>Psychological Medicine</i> , <b>2022</b> , 1-19	6.9	2
543	Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.. <i>World Psychiatry</i> , <b>2022</b> , 21, 295-307	14.4	2

542	The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations.. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 59, 45-55	1.2	0
541	Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12-43 years. <i>Psychological Medicine</i> , <b>2021</b> , 51, 1570-1580	6.9	9
540	Appraising the effectiveness of electrical and magnetic brain stimulation techniques in acute major depressive episodes: an umbrella review of meta-analyses of randomized controlled trials. <i>Revista Brasileira De Psiquiatria</i> , <b>2021</b> , 43, 514-524	2.6	11
539	CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , <b>2021</b> , 41, 667-672	1.7	1
538	Long-term efficacy and safety of once-monthly Risperidone ISM <sup>®</sup> in the treatment of schizophrenia: Results from a 12-month open-label extension study. <i>Schizophrenia Research</i> , <b>2021</b> , 239, 83-91	3.6	0
537	A large scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic.. <i>Journal of Medical Virology</i> , <b>2021</b> ,	19.7	9
536	Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms. <i>European Psychiatry</i> , <b>2021</b> , 1-27	6	3
535	Symptoms and Characteristics of Youth Hospitalized for Depression: Subthreshold Manic Symptoms Can Help Differentiate Bipolar from Unipolar Depression. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2021</b> , 31, 545-552	2.9	0
534	Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. <i>CNS Drugs</i> , <b>2021</b> , 35, 1189-1205	6.7	3
533	Longitudinal Course of Depressive, Anxiety, and Posttraumatic Stress Disorder Symptoms After Heart Surgery: A Meta-Analysis of 94 Studies. <i>Psychosomatic Medicine</i> , <b>2021</b> , 83, 85-93	3.7	4
532	Age dependency of body mass index distribution in childhood and adolescent inpatients with anorexia nervosa with a focus on DSM-5 and ICD-11 weight criteria and severity specifiers. <i>European Child and Adolescent Psychiatry</i> , <b>2021</b> , 30, 1081-1094	5.5	6
531	Emotional abuse interacts with borderline personality in adolescent inpatients with binge-purging eating disorders. <i>Eating and Weight Disorders</i> , <b>2021</b> , 1	3.6	1
530	Effectiveness of Transdiagnostic Cognitive-Behavioral Psychotherapy Compared With Management as Usual for Youth With Common Mental Health Problems: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , <b>2021</b> , 78, 250-260	14.5	8
529	Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 35, 1081-1090	4.6	3
528	Cardiometabolic Safety of Lumateperone (ITI-007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study in Schizophrenia. <i>CNS Spectrums</i> , <b>2021</b> , 26, 152	1.8	1
527	How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. <i>Revista Brasileira De Psiquiatria</i> , <b>2021</b> , 43, 189-202	2.6	9
526	How to Estimate QT Interval in Patients With Left or Right Bundle Branch Block: A Systematic Review. <i>Journal of Clinical Psychopharmacology</i> , <b>2021</b> , 41, 323-326	1.7	1
525	Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study. <i>CNS Spectrums</i> , <b>2021</b> , 26, 148-149	1.8	8

524	Systematic review of transdermal treatment options in attention-deficit/hyperactivity disorder: implications for use in adult patients. <i>CNS Spectrums</i> , <b>2021</b> , 1-13	1.8	
523	Occurrence and accuracy of a register-based diagnosis of pediatric bipolar disorder: A nationwide cohort study. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2021</b> , 55, 1101-1108	2.6	0
522	Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. <i>Lancet Psychiatry</i> , <b>2021</b> , 8, 387-404	23.3	43
521	Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Non-affective Psychoses: A Network Meta-Analysis. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 424-436	11.9	22
520	Association of Low-Dose Quetiapine and Diabetes. <i>JAMA Network Open</i> , <b>2021</b> , 4, e213209	10.4	1
519	Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 1621-1630	1.3	3
518	Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , <b>2021</b> , 78, 510-518	14.5	13
517	Preventive psychiatry: a blueprint for improving the mental health of young people. <i>World Psychiatry</i> , <b>2021</b> , 20, 200-221	14.4	48
516	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. <i>World Psychiatry</i> , <b>2021</b> , 20, 244-275	14.4	12
515	Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Psychiatry</i> , <b>2021</b> , 8, 471-486	23.3	5
514	Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 360	8.6	1
513	Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. <i>EClinicalMedicine</i> , <b>2021</b> , 36, 100909	11.3	8
512	Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	116
511	Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 1611-1620	1.3	7
510	Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2021</b> , 31, 364-375	2.9	1
509	Long-acting injectable versus oral antipsychotics for schizophrenia - Authors' Reply. <i>Lancet Psychiatry</i> , <b>2021</b> , 8, 567	23.3	2
508	Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 4081-4094	2.3	1
507	Early detection of bipolar disorders and treatment recommendations for help-seeking adolescents and young adults: Findings of the Early Detection and Intervention Center Dresden. <i>International Journal of Bipolar Disorders</i> , <b>2021</b> , 9, 23	5.4	0

506	The Collaborative Outcomes study on Health and Functioning during Infection Times in Adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic.. <i>Journal of Affective Disorders</i> , <b>2021</b> , 299, 393-393	6.6	2
505	Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. <i>Bipolar Disorders</i> , <b>2021</b> , 23, 117-129	3.8	11
504	Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , <b>2021</b> , 62, 657-673	7.9	42
503	Systematic identification and stratification of help-seeking school-aged youth with mental health problems: a novel approach to stage-based stepped-care. <i>European Child and Adolescent Psychiatry</i> , <b>2021</b> , 1	5.5	1
502	What is the Best Latent Structure of Negative Symptoms in Schizophrenia? A Systematic Review.. <i>Schizophrenia Bulletin Open</i> , <b>2021</b> , 2, sgab013	2.2	2
501	Risk and protective factors for mental disorders with onset in childhood/adolescence: An umbrella review of published meta-analyses of observational longitudinal studies. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2021</b> , 120, 565-573	9	6
500	Mortality After the First Diagnosis of Schizophrenia-Spectrum Disorders: A Population-based Retrospective Cohort Study. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 864-874	1.3	5
499	Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 948-958	1.3	6
498	Clinical validation of the Symptom Self-rating Scale for Schizophrenia (4S) among inpatients. <i>Nordic Journal of Psychiatry</i> , <b>2021</b> , 75, 454-464	2.3	1
497	Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. <i>Schizophrenia Research</i> , <b>2021</b> , 228, 198-205	3.6	7
496	Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6). <i>Schizophrenia Research</i> , <b>2021</b> , 228, 438-446	3.6	1
495	Discrepancies between staff and gold standard ratings of schizophrenia symptom severity. <i>Psychiatry Research</i> , <b>2021</b> , 301, 113963	9.9	
494	Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. <i>Schizophrenia Bulletin</i> , <b>2021</b> ,	1.3	5
493	Validity of the Aktibipo Self-rating Questionnaire for the Digital Self-assessment of Mood and Relapse Detection in Patients With Bipolar Disorder: Instrument Validation Study. <i>JMIR Mental Health</i> , <b>2021</b> , 8, e26348	6	
492	Long-acting antipsychotics: is what we know really so? - AuthorsQepl. <i>Lancet Psychiatry,the</i> , <b>2021</b> , 8, 651-652	23.3	
491	Developing an International Standard Set of Patient-Reported Outcome Measures for Psychotic Disorders. <i>Psychiatric Services</i> , <b>2021</b> , appips202000888	3.3	2
490	A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. <i>Acta Psychiatrica Scandinavica</i> , <b>2021</b> , 144, 329-341	6.5	8
489	Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. <i>Schizophrenia Bulletin</i> , <b>2021</b> ,	1.3	6

488	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis. <i>NPJ Schizophrenia</i> , <b>2021</b> , 7, 41	5.5	2
487	Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review. <i>European Neuropsychopharmacology</i> , <b>2021</b> , 54, 90-90	1.2	1
486	Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. <i>World Psychiatry</i> , <b>2021</b> , 20, 417-436	14.4	21
485	Individuals at increased risk for development of bipolar disorder display structural alterations similar to people with manifest disease. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 485	8.6	2
484	Withdrawal-associated relapse is a potential source of bias - Authors Reply. <i>Lancet Psychiatry</i> , <b>2021</b> , 8, 748-749	23.3	
483	Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 793-803	11.9	8
482	Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. <i>Lancet Psychiatry</i> , <b>2021</b> , 8, 883-891	23.3	13
481	Primary prevention of depression: An umbrella review of controlled interventions. <i>Journal of Affective Disorders</i> , <b>2021</b> , 294, 957-970	6.6	8
480	Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. <i>CNS Drugs</i> , <b>2021</b> , 35, 39-59	6.7	12
479	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 986-996	1.3	0
478	What are the physical and mental health implications of duration of untreated psychosis?. <i>European Psychiatry</i> , <b>2021</b> , 64, e46	6	
477	Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. <i>NPJ Schizophrenia</i> , <b>2021</b> , 7, 63	5.5	7
476	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , <b>2021</b> , 55,	2	11
475	Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review.. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 808002	5	3
474	Reasons for admission and variance of body weight at referral in female inpatients with anorexia nervosa in Germany.. <i>Child and Adolescent Psychiatry and Mental Health</i> , <b>2021</b> , 15, 78	6.8	0
473	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , <b>2020</b> , 45, 222-223	4.5	50
472	Clozapine and COVID-19: The authors respond. <i>Journal of Psychiatry and Neuroscience</i> , <b>2020</b> , 45, E1-E2	4.5	1
471	Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, 1459-1470	1.3	16

470	The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2020</b> , 30, 376-380	2.9	7
469	Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. <i>World Psychiatry</i> , <b>2020</b> , 19, 214-232	14.4	57
468	Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , <b>2020</b> , 23, 491-495	5.8	1
467	Efficacy of cognitive-behavioral group therapy in patients at risk for serious mental illness presenting with subthreshold bipolar symptoms: Results from a prespecified interim analysis of a multicenter, randomized, controlled study. <i>Bipolar Disorders</i> , <b>2020</b> , 22, 517-529	3.8	9
466	Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. <i>JAMA Psychiatry</i> , <b>2020</b> , 77, 755-765	14.5	143
465	Assessment of Physical Activity Patterns in Adolescent Patients with Anorexia Nervosa and Their Effect on Weight Gain. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
464	Management of Patients With Severe Mental Illness During the Coronavirus Disease 2019 Pandemic. <i>JAMA Psychiatry</i> , <b>2020</b> , 77, 977-978	14.5	31
463	The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. <i>CNS Spectrums</i> , <b>2020</b> , 1-25	1.8	6
462	Psychological and nutritional correlates of objectively assessed physical activity in patients with anorexia nervosa. <i>European Eating Disorders Review</i> , <b>2020</b> , 28, 559-570	5.3	3
461	The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index. <i>BMC Psychiatry</i> , <b>2020</b> , 20, 77	4.2	3
460	Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. <i>Neuropsychiatric Disease and Treatment</i> , <b>2020</b> , 16, 519-534	3.1	128
459	Demographic and Clinical Characteristics, Including Subsyndromal Symptoms Across Bipolar-Spectrum Disorders in Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2020</b> , 30, 222-234	2.9	4
458	A symptom combination predicting treatment-resistant schizophrenia - A strategy for real-world clinical practice. <i>Schizophrenia Research</i> , <b>2020</b> , 218, 195-200	3.6	4
457	Frequency and Correlates of Acute Dystonic Reactions After Antipsychotic Initiation in 441 Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2020</b> , 30, 366-375	2.9	1
456	Cultural Influences in Psychiatry-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 1193-1194	27.4	
455	100 Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study. <i>CNS Spectrums</i> , <b>2020</b> , 25, 265-265	1.8	1
454	104 Long-term Efficacy of Lurasidone in Antipsychotic-naïve vs. Antipsychotic-exposed Adolescents with Schizophrenia: Analysis of a Two-Year Study. <i>CNS Spectrums</i> , <b>2020</b> , 25, 267-268	1.8	
453	Long-term outcome of early-onset compared to adult-onset schizophrenia: A nationwide Danish register study. <i>Schizophrenia Research</i> , <b>2020</b> , 220, 123-129	3.6	6

452	The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. <i>Focus (American Psychiatric Publishing)</i> , <b>2020</b> , 18, 456-465	1.1	4
451	Improving early recognition and intervention in people at increased risk for the development of bipolar disorder: study protocol of a prospective-longitudinal, naturalistic cohort study (Early-BipoLife). <i>International Journal of Bipolar Disorders</i> , <b>2020</b> , 8, 22	5.4	7
450	Diagnostic stability in children and adolescents with bipolar disorder, a nationwide register-based study. <i>International Journal of Bipolar Disorders</i> , <b>2020</b> , 8, 14	5.4	3
449	Suicidality in Childhood and Adolescence. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2020</b> , 117, 261-267	2.5	3
448	Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives. <i>Future Neurology</i> , <b>2020</b> , 15, FNL52	1.5	3
447	Outcomes of an Accelerated Inpatient Refeeding Protocol in 103 Extremely Underweight Adults with Anorexia Nervosa at a Specialized Clinic in Prien, Germany. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
446	Antipsychotic Polypharmacy in Schizophrenia: Why Not?. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	11
445	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft f#x00f;r Neuropsychopharmakologie und Pharmakopsychiatrie. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	39
444	Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	12
443	Current Treatment Options and Emerging Agents for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	5
442	Using Patient-Centered Assessment in Schizophrenia Care: Defining Recovery and Discussing Concerns and Preferences. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	5
441	Drs Kane and Correll Reply. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	
440	Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 35, 1-11	1.2	6
439	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2020</b> , 270, 83-94	5.1	3
438	Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. <i>JAMA Psychiatry</i> , <b>2020</b> , 77, 225-226	14.5	5
437	Incontinence and constipation in adolescent patients with anorexia nervosa-Results of a multicenter study from a German web-based registry for children and adolescents with anorexia nervosa. <i>International Journal of Eating Disorders</i> , <b>2020</b> , 53, 219-228	6.3	7
436	20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). <i>World Psychiatry</i> , <b>2020</b> , 19, 61-68	14.4	107
435	The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. <i>NPJ Schizophrenia</i> , <b>2020</b> , 6, 1	5.5	79



434	Measuring movements in adolescents with psychosis using the Microsoft Kinect sensor: a pilot study exploring a new tool for assessing aspects of antipsychotic-induced parkinsonism. <i>Child and Adolescent Mental Health</i> , <b>2020</b> , 25, 79-94	2.2	
433	Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , <b>2020</b> , 77, 349-358	14.5	108
432	Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. <i>World Psychiatry</i> , <b>2020</b> , 19, 69-80	14.4	34
431	Metabolic Monitoring Rates of Youth Treated with Second-Generation Antipsychotics in Usual Care: Results of a Large US National Commercial Health Plan. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2020</b> , 30, 119-122	2.9	8
430	Better care for less money: cost-effectiveness of integrated care in multi-episode patients with severe psychosis. <i>Acta Psychiatrica Scandinavica</i> , <b>2020</b> , 141, 221-230	6.5	4
429	Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain-related functional pathways. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2020</b> , 183, 140-151	3.5	
428	Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. <i>Schizophrenia Research</i> , <b>2020</b> , 225, 55-62	3.6	12
427	Most recommended medical interventions reach P . <i>International Journal of Epidemiology</i> , <b>2020</b> , 49, 885-893	3.3	5
426	Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people. <i>Lancet Psychiatry</i> , <b>2020</b> , 7, 52-63	23.3	45
425	What is good mental health? A scoping review. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 31, 33-46	1.2	40
424	M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, S214-S214	1.3	1
423	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. <i>Schizophrenia Bulletin Open</i> , <b>2020</b> , 1,	2.2	1
422	Medical management of eating disorders: an update. <i>Current Opinion in Psychiatry</i> , <b>2020</b> , 33, 542-553	4.9	4
421	Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. <i>Lancet Psychiatry</i> , <b>2020</b> , 7, 749-761	23.3	25
420	Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. <i>CNS Spectrums</i> , <b>2020</b> , 1-11	1.8	6
419	How mental health care should change as a consequence of the COVID-19 pandemic. <i>Lancet Psychiatry</i> , <b>2020</b> , 7, 813-824	23.3	542
418	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , <b>2020</b> , 18, 215	11.4	30
417	DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 568982	5	3

416	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 77, 141-145	3.6	0
415	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 41, 28-39	1.2	25
414	Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2020</b> , 10, 2045125320942703	4.9	13
413	Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 1168-1178	11.9	25
412	Motor activity patterns can distinguish between interepisode bipolar disorder patients and healthy controls. <i>CNS Spectrums</i> , <b>2020</b> , 1-11	1.8	4
411	Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. <i>Drugs</i> , <b>2020</b> , 80, 1763-1781	12.1	10
410	Association between mental disorders and somatic conditions: protocol for an umbrella review. <i>Evidence-Based Mental Health</i> , <b>2020</b> , 23, 135-139	11.1	10
409	Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. <i>Psychological Medicine</i> , <b>2020</b> , 50, 1356-1367	6.9	13
408	Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 41-49	2.8	6
407	Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. <i>Schizophrenia Research</i> , <b>2020</b> , 215, 408-415	3.6	19
406	Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, 1547-1557	1.3	12
405	Exploring Movement Impairments in Patients With Parkinson Disease Using the Microsoft Kinect Sensor: A Feasibility Study. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 610614	4.1	2
404	O12.1. CARDIOMETABOLIC ADVERSE EFFECTS AND ITS PREDICTORS IN CHILDREN AND ADOLESCENTS WITH FIRST-EPISODE PSYCHOSIS DURING TREATMENT WITH QUETIAPINE-ER VERSUS ARIPIPRAZOLE: 12-WEEK RESULTS: FROM THE TEA TRIAL. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, S197-S197	1.3	78
403	Mullerian inhibiting substance, sex hormone binding globulin and sex hormone levels in stimulant-naïve, first-diagnosed prepubertal boys with attention-deficit/hyperactivity disorder: comparison with matched healthy controls as well as before and after oros-methylphenidate treatment. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2019</b> , 23, 251-257	2.4	3
402	Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. <i>CNS Spectrums</i> , <b>2019</b> , 24, 38-69	1.8	51
401	An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. <i>Journal of Psychopharmacology</i> , <b>2019</b> , 33, 1227-1236	4.6	13
400	Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210674	3.7	1
399	Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. <i>Neuropsychiatric Disease and Treatment</i> , <b>2019</b> , 15, 2597-2550	3.1	15

398	Lifestyle Interventions for Weight Management in People with Serious Mental Illness: A Systematic Review with Meta-Analysis, Trial Sequential Analysis, and Meta-Regression Analysis Exploring the Mediators and Moderators of Treatment Effects. <i>Psychotherapy and Psychosomatics</i> , <b>2019</b> , 88, 350-362	9.4	26
397	Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 1241-1255	14.5	72
396	Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can't). <i>Evidence-Based Mental Health</i> , <b>2019</b> , 22, e3	11.1	1
395	Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. <i>Movement Disorders</i> , <b>2019</b> , 34, 1203-1209	7	7
394	Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , <b>2019</b> , 15, 1365-1379	3.1	14
393	Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. <i>World Psychiatry</i> , <b>2019</b> , 18, 208-224	14.4	53
392	Longitudinal outcomes in pediatric- and adult-onset bipolar patients compared to healthy and schizophrenia controls. <i>Bipolar Disorders</i> , <b>2019</b> , 21, 514-524	3.8	4
391	Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2019</b> , 58, 1062-1078	7.2	10
390	84 Assessment of Current Clinical Practices in Recognizing and Treating Bipolar Disorder. <i>CNS Spectrums</i> , <b>2019</b> , 24, 217-218	1.8	
389	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 1109-1116	2.8	6
388	Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. <i>Psychiatry Research</i> , <b>2019</b> , 274, 176-181	9.9	7
387	Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, "real world" clinical trial. <i>Psychiatry Research</i> , <b>2019</b> , 273, 631-640	9.9	5
386	Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 1052-1062	14.5	111
385	The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. <i>Lancet Psychiatry</i> , <b>2019</b> , 6, 675-712	23.3	411
384	Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. <i>Acta Psychiatrica Scandinavica</i> , <b>2019</b> , 140, 227-243	6.5	36
383	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 1301-1311	1.2	22
382	Clinical Characteristics of Inpatients with Childhood vs. Adolescent Anorexia Nervosa. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	10
381	Is Transcultural Psychiatry Possible?. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 2167-2168	2.1	9

380	Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. <i>BMC Psychiatry</i> , <b>2019</b> , 19, 362	4.2	12
379	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. <i>Bipolar Disorders</i> , <b>2019</b> , 21, 720-740	3.8	32
378	Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	20
377	Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 499-507	14.5	106
376	Bipolar Prodrome Symptom Scale - Abbreviated Screen for Patients: Description and validation. <i>Journal of Affective Disorders</i> , <b>2019</b> , 249, 357-365	6.6	11
375	Patches: Established and Emerging Transdermal Treatments in Psychiatry. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	10
374	Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	9
373	Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	66
372	Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019. <i>Current Psychiatry Reports</i> , <b>2019</b> , 21, 124	9.1	9
371	Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 293-302	6.7	40
370	Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. <i>CNS Spectrums</i> , <b>2019</b> , 24, 479-495	1.8	12
369	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. <i>CNS Spectrums</i> , <b>2019</b> , 24, 441-452	1.8	8
368	Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. <i>CNS Spectrums</i> , <b>2019</b> , 24, 354-370	1.8	10
367	One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. <i>Acta Psychiatrica Scandinavica</i> , <b>2019</b> , 139, 26-36	6.5	19
366	Creativity in persons at-risk for bipolar disorder-A pilot study. <i>Microbial Biotechnology</i> , <b>2019</b> , 13, 1165-1173	3.3	4
365	Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. <i>CNS Spectrums</i> , <b>2019</b> , 24, 507-517	1.8	9
364	Rhythmic low-field magnetic stimulation may improve depression by increasing brain-derived neurotrophic factor. <i>CNS Spectrums</i> , <b>2019</b> , 24, 313-321	1.8	9
363	Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 315-329	1.3	87

362	Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. <i>Epidemiology and Psychiatric Sciences</i> , <b>2019</b> , 29, e14	5.1	6
361	A simulations approach for meta-analysis of genetic association studies based on additive genetic model. <i>Meta Gene</i> , <b>2018</b> , 16, 143-164	0.7	1
360	The role of genetic variation of human metabolism for BMI, mental traits and mental disorders. <i>Molecular Metabolism</i> , <b>2018</b> , 12, 1-11	8.8	12
359	O7.2. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION IN A CLINICAL COHORT. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S93-S94	1.3	78
358	Clinical risk factors for the development of tardive dyskinesia. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 389, 21-27	3.2	64
357	Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2018</b> , 137, 187-205	6.5	35
356	National Patterns of Commonly Prescribed Psychotropic Medications to Young People. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2018</b> , 28, 158-165	2.9	29
355	The pharmacological management of metabolic syndrome. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 397-410	3.8	56
354	Validation study of the early onset schizophrenia diagnosis in the Danish Psychiatric Central Research Register. <i>European Child and Adolescent Psychiatry</i> , <b>2018</b> , 27, 965-975	5.5	10
353	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 555-565	14.5	293
352	S98. THE RELATIONSHIP BETWEEN CARDIOVASCULAR RISK FACTORS AND COGNITIVE IMPAIRMENT IN PEOPLE WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S363-S363	1.3	78
351	Demographic and clinical correlates of substance use disorders in first episode psychosis. <i>Schizophrenia Research</i> , <b>2018</b> , 194, 4-12	3.6	44
350	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 603-619	1.3	99
349	Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 169-179	11.9	30
348	ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. <i>Journal of Psychiatric Research</i> , <b>2018</b> , 105, 23-32	5.2	42
347	Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1. <i>Neuropsychiatric Disease and Treatment</i> , <b>2018</b> , 14, 1463-1474	3.1	17
346	Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. <i>Evidence-Based Mental Health</i> , <b>2018</b> , 21, e11	11.1	
345	The role of meta-analyses and umbrella reviews in assessing the harms of psychotropic medications: beyond qualitative synthesis. <i>Epidemiology and Psychiatric Sciences</i> , <b>2018</b> , 27, 537-542	5.1	17

344	Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. <i>Neuropsychiatric Disease and Treatment</i> , <b>2018</b> , 14, 1473-1492 <sup>14</sup>	3.1	1492
343	Systematic review and guide to management of core and psychiatric symptoms in youth with autism. <i>Acta Psychiatrica Scandinavica</i> , <b>2018</b> , 138, 379-400	6.5	24
342	Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?. <i>Journal of Clinical Psychiatry</i> , <b>2018</b> , 79,	4.6	3
341	Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis. <i>Journal of Clinical Psychiatry</i> , <b>2018</b> , 79,	4.6	16
340	A systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia. <i>Journal of Neural Transmission</i> , <b>2018</b> , 125, 89-102	4.3	16
339	A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. <i>Schizophrenia Research</i> , <b>2018</b> , 195, 245-251	3.6	28
338	Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. <i>Psychopharmacology</i> , <b>2018</b> , 235, 681-693	4.7	4
337	Real-World Effectiveness of Clozapine for Borderline Personality Disorder: Results From a 2-Year Mirror-Image Study. <i>Journal of Personality Disorders</i> , <b>2018</b> , 32, 823-837	2.6	13
336	Comorbidity of chronic somatic diseases in patients with psychotic disorders and their influence on 4-year outcomes of integrated care treatment (ACCESS II study). <i>Schizophrenia Research</i> , <b>2018</b> , 193, 377-383	3.6	11
335	144 A Clinical Practice Assessment In Tardive Dyskinesia: Are Physicians Up-to-Date?. <i>CNS Spectrums</i> , <b>2018</b> , 23, 89-90	1.8	
334	Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. <i>BMC Psychiatry</i> , <b>2018</b> , 18, 365	4.2	9
333	Mobility for All?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2018</b> , 57, 792-793	7.2	
332	The Role of Objectively Measured, Altered Physical Activity Patterns for Body Mass Index Change during Inpatient Treatment in Female Patients with Anorexia Nervosa. <i>Journal of Clinical Medicine</i> , <b>2018</b> , 7,	5.1	9
331	EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). <i>European Psychiatry</i> , <b>2018</b> , 54, 124-144	6	197
330	Digital Trajectories to Care in First-Episode Psychosis. <i>Psychiatric Services</i> , <b>2018</b> , 69, 1259-1263	3.3	15
329	Disturbing Lack of Early Intervention Studies in Bipolar Disorder-Reply. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 1202-1203	4.9	
328	Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , <b>2018</b> , 33, 322-329	2.2	7
327	The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2018</b> , 8, 303-318	4.9	76

326	O5.1. CLOZAPINE AND LONG-TERM MORTALITY RISK IN PATIENTS WITH SCHIZOPHRENIA: PRELIMINARY RESULTS FROM A META-ANALYSIS. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S86-S86	1.3	5
325	Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. <i>World Psychiatry</i> , <b>2018</b> , 17, 330-340	14.4	73
324	Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. <i>Drug Design, Development and Therapy</i> , <b>2018</b> , 12, 1215-1238	4.4	36
323	S46. THE VALIDITY AND SENSITIVITY OF PANSS-6 IN TREATMENT-RESISTANT SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S341-S342	1.3	78
322	Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8,288 Patients. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 570-576	1.7	12
321	What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. <i>World Psychiatry</i> , <b>2018</b> , 17, 149-160	14.4	116
320	S27. RELIABILITY OF SCHIZOPHRENIA DIAGNOSES IN CHILDREN AND ADOLESCENTS IN DENMARK. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S333-S333	1.3	78
319	Insomnia in Adults With Chronic Hepatitis B, Liver Failure, and Cirrhosis: A Case-Control Study. <i>Perspectives in Psychiatric Care</i> , <b>2017</b> , 53, 67-72	2.2	6
318	Investigational drugs in recent clinical trials for treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , <b>2017</b> , 17, 593-609	4.3	46
317	Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy. <i>Psychiatry Research</i> , <b>2017</b> , 248, 134-139	9.9	4
316	Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. <i>Ageing Research Reviews</i> , <b>2017</b> , 35, 63-73 <sup>12</sup>		112
315	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , <b>2017</b> , 16, 77-89	14.4	109
314	Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings. <i>Evidence-Based Mental Health</i> , <b>2017</b> , 20, e6	11.1	5
313	Pain perception in Parkinson@ disease: A systematic review and meta-analysis of experimental studies. <i>Ageing Research Reviews</i> , <b>2017</b> , 35, 74-86	12	24
312	Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. <i>CNS Spectrums</i> , <b>2017</b> , 22, 415-426	1.8	48
311	Impairment in Social Functioning differentiates youth meeting Ultra-High Risk for psychosis criteria from other mental health help-seekers: A validation of the Italian version of the Global Functioning: Social and Global Functioning: Role scales. <i>Psychiatry Research</i> , <b>2017</b> , 253, 296-302	9.9	9
310	Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. <i>World Psychiatry</i> , <b>2017</b> , 16, 163-180	14.4	688
309	A Severity-Based Clinical Staging Model for the Psychosis Prodrome: Longitudinal Findings From the New York Recognition and Prevention Program. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, 64-74	1.3	38

308	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. <i>JAMA Psychiatry</i> , <b>2017</b> , 74, 675-684	14.5	94
307	EB Polyunsaturated Fatty Acids to Prevent Psychosis: The Importance of Replication Studies. <i>JAMA Psychiatry</i> , <b>2017</b> , 74, 11-12	14.5	8
306	Analgesic Effects of Alcohol: A Systematic Review and Meta-Analysis of Controlled Experimental Studies in Healthy Participants. <i>Journal of Pain</i> , <b>2017</b> , 18, 499-510	5.2	73
305	Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A Nation-wide pharmacoepidemiological study. <i>Psychiatry Research</i> , <b>2017</b> , 255, 198-203	9.9	6
304	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , <b>2017</b> , 74, 719-728	14.5	80
303	Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. <i>Lancet Psychiatry</i> , <b>2017</b> , 4, 605-618	23.3	33
302	Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2017</b> , 7, 1-14	4.9	14
301	Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. <i>Schizophrenia Research</i> , <b>2017</b> , 185, 167-172	3.6	15
300	Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain-Reply. <i>JAMA Psychiatry</i> , <b>2017</b> , 74, 1173-1174	14.5	2
299	The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. <i>Bipolar Disorders</i> , <b>2017</b> , 19, 524-543	3.8	95
298	Catechol-O-Methyltransferase (COMT) Val158Met Polymorphism and Eating Disorders: Data From a New Biobank and Meta-Analysis of Previously Published Studies. <i>European Eating Disorders Review</i> , <b>2017</b> , 25, 524-532	5.3	6
297	Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, e933-e939	4.6	27
296	Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2017</b> , 56, 784-792	7.2	17
295	A new class of VMAT-2 inhibitors for tardive dyskinesia. <i>Lancet Psychiatry</i> , <b>2017</b> , 4, 574-575	23.3	3
294	Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of , and Variants with Negative Symptoms and Cognitive Deficits. <i>Frontiers in Psychiatry</i> , <b>2017</b> , 8, 292	5	11
293	Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Therapeutics and Clinical Risk Management</i> , <b>2017</b> , 13, 757-777	2.9	194
292	Leptin and Physical Activity in Adult Patients with Anorexia Nervosa: Failure to Demonstrate a Simple Linear Association. <i>Nutrients</i> , <b>2017</b> , 9,	6.7	12
291	Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. <i>Psychopharmacology Bulletin</i> , <b>2017</b> , 47, 53-60	0.9	12



290	Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. <i>Psychopharmacology Bulletin</i> , <b>2017</b> , 47, 69-76	0.9	12
289	Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, e1035-e1046	4.6	25
288	Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, e744-e781	4.6	16
287	Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, e1158-e1166	4.6	3
286	Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, e264-e278	4.6	13 <sup>1</sup>
285	Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors: A Systematic Review. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, e957-e969	4.6	21
284	The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, 1344-1350	4.6	56
283	Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, 1136-1147	4.6	42
282	Epidemiology and Prevention of Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, e1426	4.6	4
281	Extent, Time Course, and Moderators of Antipsychotic Treatment in Youth With Mood Disorders: Results of a Meta-Analysis and Meta-Regression Analyses. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, 347-357	4.6	1
280	Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 362-72	11.9	43 <sup>1</sup>
279	Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. <i>CNS Spectrums</i> , <b>2016</b> , 21, 466-477	1.8	10
278	Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. <i>BMC Medicine</i> , <b>2016</b> , 14, 189	11.4	84
277	Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. <i>Psychiatric Services</i> , <b>2016</b> , 67, 1035-8	3.3	18
276	Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. <i>Journal of Psychiatric Research</i> , <b>2016</b> , 81, 95-101	5.2	49
275	Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. <i>CNS Spectrums</i> , <b>2016</b> , 21, 393-402	1.8	22
274	Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2016</b> , 26, 458-70	2.9	14
273	Adaptation of a peer based online emotional support program as an adjunct to treatment for people with schizophrenia-spectrum disorders. <i>Internet Interventions</i> , <b>2016</b> , 4, 35-42	4.4	17

272	Self-Reported and Interviewer-Rated Oral Health in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. <i>Perspectives in Psychiatric Care</i> , <b>2016</b> , 52, 4-11	2.2	12
271	Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , <b>2016</b> , 73, 247-59	14.5	151
270	Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. <i>Journal of Affective Disorders</i> , <b>2016</b> , 197, 268-80	6.6	14
269	Smoking in male patients with schizophrenia in China: A meta-analysis. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 162, 146-53	4.9	29
268	Worldwide Differences in Regulations of Clozapine Use. <i>CNS Drugs</i> , <b>2016</b> , 30, 149-61	6.7	100
267	The Role of Clozapine in Treatment-Resistant Schizophrenia. <i>JAMA Psychiatry</i> , <b>2016</b> , 73, 187-8	14.5	53
266	Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 921-36	4	22
265	Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 591-612	4.1	24
264	Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. <i>European Child and Adolescent Psychiatry</i> , <b>2016</b> , 25, 1091-102	5.5	24
263	Poor Sleep Is Related to Lower Emotional Competence Among Adolescents. <i>Behavioral Sleep Medicine</i> , <b>2016</b> , 14, 602-14	4.2	53
262	Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review. <i>Shanghai Archives of Psychiatry</i> , <b>2016</b> , 28, 241-252		4
261	The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, 1-24	4.6	173
260	Low Hemoglobin Levels and Risk of Developing Depression in the Elderly: Results From the Prospective PRO.V.A. Study. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, e1549-e1556	4.6	15
259	Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, e746-56	4.6	25
258	The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. <i>Addiction</i> , <b>2016</b> , 111, 1914-1922	4.6	47
257	Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. <i>CNS Drugs</i> , <b>2016</b> , 30, 997-1006	6.7	7
256	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. <i>Psychoneuroendocrinology</i> , <b>2016</b> , 72, 1-10	5	21
255	Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. <i>Psychological Medicine</i> , <b>2016</b> , 46, 623-35	6.9	80

254	Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , <b>2016</b> , 133, 341-51	6.5	66
253	Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2016</b> , 26, 740-749	2.9	43
252	Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. <i>Schizophrenia Research</i> , <b>2016</b> , 174, 93-98	3.6	41
251	Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia. <i>Schizophrenia Research</i> , <b>2016</b> , 174, 71-76	3.6	38
250	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 1418-1437	1.3	103
249	Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia. <i>Epidemiology and Psychiatric Sciences</i> , <b>2016</b> , 25, 9-17	5.1	17
248	Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms. <i>Psychological Medicine</i> , <b>2016</b> , 46, 1069-78	6.9	18
247	The Bipolar Prodrome: Meta-Analysis of Symptom Prevalence Prior to Initial or Recurrent Mood Episodes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2016</b> , 55, 543-55	7.2	83
246	Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. <i>Schizophrenia Research</i> , <b>2016</b> , 174, 82-92	3.6	35
245	ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. <i>Expert Review of Neurotherapeutics</i> , <b>2016</b> , 16, 601-14	4.3	26
244	Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2016</b> , 55, 456-468.e4	7.2	46
243	Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. <i>Psychological Medicine</i> , <b>2016</b> , 46, 1459-72	6.9	210
242	Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2016</b> , 26, 410-27	2.9	69
241	Premature Mortality and Schizophrenia-The Need to Heal Right From the Start. <i>JAMA Psychiatry</i> , <b>2016</b> , 73, 535-6	14.5	5
240	Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. <i>Acta Psychiatrica Scandinavica</i> , <b>2016</b> , 134, 385-398	6.5	39
239	Is Pain Perception Altered in People With Depression? A Systematic Review and Meta-Analysis of Experimental Pain Research. <i>Journal of Pain</i> , <b>2016</b> , 17, 1257-1272	5.2	75
238	Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. <i>Schizophrenia Research</i> , <b>2016</b> , 176, 220-230	3.6	70
237	Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. <i>World Psychiatry</i> , <b>2016</b> , 15, 166-74	14.4	365

236	Prevalence of aggression in hospitalized patients with schizophrenia in China: A meta-analysis. <i>Asia-Pacific Psychiatry</i> , <b>2016</b> , 8, 60-9	3.2	32
235	Vitamin K antagonists use and fracture risk: results from a systematic review and meta-analysis: reply. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 221-3	15.4	1
234	Temperament and prodromal symptoms prior to first manic/hypomanic episodes: results from a pilot study. <i>Journal of Affective Disorders</i> , <b>2015</b> , 173, 39-44	6.6	15
233	A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. <i>Psychological Medicine</i> , <b>2015</b> , 45, 299-317	6.9	68
232	Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2015</b> , 54, 718-727.e3	7.2	26
231	Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 1513-31	1.2	37
230	Importando la Escala de Síntomas Prodrómicos Bipolares-Prospectiva Completa.. <i>Psiquiatria Biologica</i> , <b>2015</b> , 22, 30-31	0.2	
229	Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 1669-76	1.2	19
228	Glutamatergic agents for schizophrenia: current evidence and perspectives. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 335-52	3.8	26
227	Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 1181-99	4.1	14
226	A functional polymorphism in the interleukin-1beta and severity of nicotine dependence in male schizophrenia: a case-control study. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 64, 51-8	5.2	6
225	Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 870-80	11.9	130
224	Suicidality and hospitalization as cause and outcome of pediatric psychiatric emergency room visits. <i>European Child and Adolescent Psychiatry</i> , <b>2015</b> , 24, 797-814	5.5	15
223	Child and adolescent psychiatrists reported monitoring behaviors for second-generation antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2015</b> , 25, 351-61	2.9	27
222	Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2015</b> , 49, 129-36	2.6	34
221	Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. <i>Current Opinion in Psychiatry</i> , <b>2015</b> , 28, 216-21	4.9	41
220	Duration of Untreated Psychosis in Community Treatment Settings in the United States. <i>Psychiatric Services</i> , <b>2015</b> , 66, 753-6	3.3	80
219	Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2015</b> , 25, 535-47	2.9	6

218	Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. <i>European Child and Adolescent Psychiatry</i> , <b>2015</b> , 24, 1485-96	5.5	11
217	Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 1587-608	4.1	15
216	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 1227-36	1.3	78
215	Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012). <i>Schizophrenia Research</i> , <b>2015</b> , 168, 523-9	3.6	13
214	Lack of cardinal symptoms of meningitis in a hospitalized patient with chronic schizophrenia: lessons to be learned. <i>General Hospital Psychiatry</i> , <b>2015</b> , 37, 621.e3-4	5.6	2
213	Do antipsychotics increase diabetes risk in children and adolescents?. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 219-41	4.1	21
212	Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2015</b> , 54, 25-36	7.2	46
211	Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 237-48	11.9	61
210	Could the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) be used in depressed schizophrenia patients?. <i>Journal of Affective Disorders</i> , <b>2015</b> , 172, 191-4	6.6	7
209	Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies. <i>Psychoneuroendocrinology</i> , <b>2015</b> , 51, 237-52	5	127
208	Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 627-36	1.3	37
207	Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. <i>World Psychiatry</i> , <b>2015</b> , 14, 56-63	14.4	71
206	Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. <i>World Psychiatry</i> , <b>2015</b> , 14, 119-36	14.4	432
205	Schizophrenia. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15067	51.1	432
204	The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis. <i>Psychological Medicine</i> , <b>2015</b> , 45, 3341-54	6.9	26
203	Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. <i>Pain</i> , <b>2015</b> , 156, 2121-2131	8	74
202	Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. <i>Acta Psychiatrica Scandinavica</i> , <b>2015</b> , 132, 97-108	6.5	149
201	Vitamin K antagonists use and fracture risk: results from a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 1665-75	15.4	31

200	Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. <i>BMC Psychiatry</i> , <b>2015</b> , 15, 271	4.2	9
199	Delayed identification and diagnosis of Huntington@ disease due to psychiatric symptoms. <i>International Journal of Mental Health Systems</i> , <b>2015</b> , 9, 33	3.6	6
198	Inverse relationship between body mass index and mortality in older nursing home residents: a meta-analysis of 19,538 elderly subjects. <i>Obesity Reviews</i> , <b>2015</b> , 16, 1001-15	10.6	92
197	Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs. <i>International Clinical Psychopharmacology</i> , <b>2015</b> , 30, 272-81	2.2	21
196	Perfectionism related to self-reported insomnia severity, but not when controlled for stress and emotion regulation. <i>Neuropsychiatric Disease and Treatment</i> , <b>2015</b> , 11, 263-71	3.1	35
195	Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , <b>2015</b> , 37, 280-8	2.6	14
194	Use of electroconvulsive therapy for Asian patients with schizophrenia (2001-2009): Trends and correlates. <i>Psychiatry and Clinical Neurosciences</i> , <b>2015</b> , 69, 489-96	6.2	23
193	Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 986-94	11.9	109
192	Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. <i>Psychoneuroendocrinology</i> , <b>2015</b> , 58, 130-40	5	40
191	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 617-29	11.9	111
190	Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. <i>World Psychiatry</i> , <b>2015</b> , 14, 339-47	14.4	627
189	Frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with nonpsychotic psychiatric disorders. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, e1449-58	4.6	18
188	Frequency and Correlates of Distant Visual Impairment in Patients with Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. <i>East Asian Archives of Psychiatry</i> , <b>2015</b> , 25, 115-21	1.1	4
187	Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40, 192-213	1.3	281
186	Prevalence of nurses@ smoking habits in psychiatric and general hospitals in China. <i>Archives of Psychiatric Nursing</i> , <b>2014</b> , 28, 119-22	2.1	7
185	Antidepressants for cognitive impairment in schizophrenia--a systematic review and meta-analysis. <i>Schizophrenia Research</i> , <b>2014</b> , 159, 385-94	3.6	33
184	Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-na@ve patients. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2014</b> , 53, 1179-90,1190.e1-4	7.2	60
183	Emerging drugs for schizophrenia: an update. <i>Expert Opinion on Emerging Drugs</i> , <b>2014</b> , 19, 511-31	3.7	38

182	SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. <i>SpringerPlus</i> , <b>2014</b> , 3, 187		10
181	BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis. <i>Schizophrenia Research</i> , <b>2014</b> , 152, 365-72	3.6	18
180	Early specific cognitive-behavioural psychotherapy in subjects at high risk for bipolar disorders: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2014</b> , 15, 161	2.8	20
179	Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2014</b> , 53, 971-979	7.2	18
178	Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2014</b> , 53, 174-87	7.2	98
177	Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2014</b> , 53, 153-73	7.2	105
176	Frequency of involuntary admissions and its associations with demographic and clinical characteristics in China. <i>Archives of Psychiatric Nursing</i> , <b>2014</b> , 28, 272-6	2.1	20
175	Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients. <i>Schizophrenia Research</i> , <b>2014</b> , 155, 72-6	3.6	56
174	Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. <i>Bipolar Disorders</i> , <b>2014</b> , 16, 478-92	3.8	68
173	Rapid clozapine titration in treatment-refractory bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2014</b> , 166, 168-72	6.6	38
172	Symptomatic and functional remission of subjects at clinical high risk for psychosis: a 2-year naturalistic observational study. <i>Schizophrenia Research</i> , <b>2014</b> , 156, 266-71	3.6	41
171	Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 1095-105	5.8	35
170	Diabetes risk potentially underestimated in youth and children receiving antipsychotics. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 209-10	14.5	13
169	Prioritization of research addressing antipsychotics for adolescents and young adults with bipolar disorder. <i>Annals of Internal Medicine</i> , <b>2014</b> , 160, 492-8	8	2
168	Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report. <i>Therapeutics and Clinical Risk Management</i> , <b>2014</b> , 10, 901-4	2.9	10
167	Child and adolescent psychiatrists' attitudes and practices prescribing second generation antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2014</b> , 24, 90-3	2.9	19
166	Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. <i>World Journal of Biological Psychiatry</i> , <b>2014</b> , 15, 229-41	3.8	15
165	Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. <i>Pediatrics</i> , <b>2014</b> , 134, e1308-14	7.4	29

164	The Bipolar Prodrome Symptom Interview and Scale-Prospicive (BPSS-P): description and validation in a psychiatric sample and healthy controls. <i>Bipolar Disorders</i> , <b>2014</b> , 16, 505-22	3.8	50
163	Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China. <i>Perspectives in Psychiatric Care</i> , <b>2014</b> , 50, 257-63	2.2	6
162	Psychotherapeutic interventions in individuals at risk of developing bipolar disorder: a systematic review. <i>Microbial Biotechnology</i> , <b>2014</b> , 8, 3-11	3.3	19
161	Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009). <i>International Journal of Geriatric Psychiatry</i> , <b>2014</b> , 29, 359-66	3.9	15
160	The prevalence and moderators of clinical pain in people with schizophrenia: a systematic review and large scale meta-analysis. <i>Schizophrenia Research</i> , <b>2014</b> , 160, 1-8	3.6	55
159	National trends in the mental health care of children, adolescents, and adults by office-based physicians. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 81-90	14.5	292
158	Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. <i>BMC Psychiatry</i> , <b>2014</b> , 14, 199	4.2	10
157	Critical issues on the use of network meta-analysis in psychiatry. <i>Harvard Review of Psychiatry</i> , <b>2014</b> , 22, 367-72	4.1	15
156	Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 1350-63	14.5	254
155	Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. <i>CNS Spectrums</i> , <b>2014</b> , 19 Suppl 1, 38-52; quiz 35-7, 53	1.8	83
154	Characteristics, symptomatology and naturalistic treatment in individuals at-risk for bipolar disorders: baseline results in the first 180 help-seeking individuals assessed at the Dresden high-risk project. <i>Journal of Affective Disorders</i> , <b>2014</b> , 152-154, 427-33	6.6	14
153	Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials. <i>BMJ Open</i> , <b>2014</b> , 4, e005708	3	7
152	Prospective memory performance in non-psychotic first-degree relatives of patients with schizophrenia: a controlled study. <i>PLoS ONE</i> , <b>2014</b> , 9, e111562	3.7	12
151	Clinical predictors of therapeutic response to antipsychotics in schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , <b>2014</b> , 16, 505-24	5.7	131
150	Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e29	4.6	8
149	The Role of the Extended Health Care Team in Successful LAI Therapy. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e25	4.6	3
148	Schizophrenia: mechanism of action of current and novel treatments. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, 347-8	4.6	10
147	National trends in second-generation antipsychotic augmentation for nonpsychotic depression. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, 490-7	4.6	30



146	Body mass index identified as an independent predictor of psychiatric readmission. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e573-7	4.6	24
145	Outcomes of SARS survivors in China: not only physical and psychiatric co-morbidities. <i>East Asian Archives of Psychiatry</i> , <b>2014</b> , 24, 37-8	1.1	20
144	Recognition of bipolar disorder type I before the first manic episode: challenges and developments. <i>Expert Review of Neurotherapeutics</i> , <b>2013</b> , 13, 795-806; quiz 807	4.3	7
143	Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 205-11	1.2	8
142	Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications. <i>Current Psychiatry Reports</i> , <b>2013</b> , 15, 382	9.1	26
141	Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions. <i>World Psychiatry</i> , <b>2013</b> , 12, 155-64	14.4	182
140	Rational use of generic psychotropic drugs. <i>CNS Drugs</i> , <b>2013</b> , 27, 353-65	6.7	19
139	Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. <i>Child and Adolescent Psychiatry and Mental Health</i> , <b>2013</b> , 7, 31	6.8	18
138	Suicidal ideation and suicide attempts in children and adolescents with bipolar disorder: a systematic review of prevalence and incidence rates, correlates, and targeted interventions. <i>Bipolar Disorders</i> , <b>2013</b> , 15, 507-23	3.8	99
137	Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales. <i>Psychiatry Research</i> , <b>2013</b> , 209, 406-11	9.9	18
136	The bipolar disorder prodrome revisited: Is there a symptomatic pattern?. <i>Journal of Affective Disorders</i> , <b>2013</b> , 151, 551-560	6.6	26
135	Antipsychotics for acute schizophrenia: making choices. <i>Lancet, The</i> , <b>2013</b> , 382, 919-20	40	13
134	Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2013</b> , 52, 689-698.e3	7.3	16
133	Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. <i>Bipolar Disorders</i> , <b>2013</b> , 15, 138-49	3.8	51
132	Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. <i>Schizophrenia Research</i> , <b>2013</b> , 143, 358-62	3.6	19
131	Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2013</b> , 23, 522-30	2.9	26
130	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. <i>Molecular Psychiatry</i> , <b>2013</b> , 18, 53-66	15.1	105
129	Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. <i>Schizophrenia Bulletin</i> , <b>2013</b> , 39, 1230-41	1.3	133

128	Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , <b>2013</b> , 16, 1205-18	5.8	186
127	Prediction of functional outcome in individuals at clinical high risk for psychosis. <i>JAMA Psychiatry</i> , <b>2013</b> , 70, 1133-42	14.5	162
126	Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. <i>Journal of ECT</i> , <b>2013</b> , 29, 271-6	2	15
125	CNR1 gene and risk of the metabolic syndrome in patients with schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 186-92	1.7	23
124	Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. <i>Current Opinion in Psychiatry</i> , <b>2013</b> , 26, 219-30	4.9	62
123	A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. <i>World Psychiatry</i> , <b>2013</b> , 12, 240-50	14.4	168
122	Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. <i>World Psychiatry</i> , <b>2013</b> , 12, 216-26	14.4	256
121	Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 265-74	11.9	272
120	Prescribing of psychotropic medications to children and adolescents: quo vadis?. <i>World Psychiatry</i> , <b>2013</b> , 12, 127-8	14.4	7
119	Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2013</b> , 23, 665-75	2.9	25
118	Frequency, characteristics and management of adolescent inpatient aggression. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2013</b> , 23, 271-81	2.9	37
117	The significance of at-risk or prodromal symptoms for bipolar I disorder in children and adolescents. <i>Canadian Journal of Psychiatry</i> , <b>2013</b> , 58, 22-31	4.8	38
116	Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. <i>Journal of Clinical Psychiatry</i> , <b>2013</b> , 74, 957-65	4.6	305
115	Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese. <i>Trends in Psychiatry and Psychotherapy</i> , <b>2013</b> , 35, 62-75	2.3	1
114	Pediatric Schizophrenia <b>2013</b> , 1-6		
113	The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. <i>Danish Medical Journal</i> , <b>2013</b> , 60, A4578	3.8	112
112	Risk constellations prior to the development of bipolar disorders: rationale of a new risk assessment tool. <i>Journal of Affective Disorders</i> , <b>2012</b> , 136, 1000-10	6.6	66
111	Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. <i>Archives of General Psychiatry</i> , <b>2012</b> , 69, 904-12		142

110	Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. <i>CNS Drugs</i> , <b>2012</b> , 26, 733-59	6.7	113
109	Safety and tolerability of antipsychotic polypharmacy. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 527-42	4.1	130
108	Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. <i>Schizophrenia Research</i> , <b>2012</b> , 140, 159-68	3.6	129
107	Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. <i>Schizophrenia Research</i> , <b>2012</b> , 138, 18-28	3.6	196
106	Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. <i>Psychiatric Clinics of North America</i> , <b>2012</b> , 35, 661-81	3.1	78
105	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. <i>Frontiers in Psychiatry</i> , <b>2012</b> , 3, 62	5	19
104	Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. <i>Pediatrics</i> , <b>2012</b> , 129, e1577-86	7.4	89
103	National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. <i>Archives of General Psychiatry</i> , <b>2012</b> , 69, 1247-56		273
102	Osteoporosis and fracture risk in people with schizophrenia. <i>Current Opinion in Psychiatry</i> , <b>2012</b> , 25, 415-29	4.9	74
101	Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 678-83	1.7	58
100	Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 458-64	1.7	11
99	Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2012</b> , 22, 166-73	2.9	15
98	Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. <i>Psychological Medicine</i> , <b>2012</b> , 42, 125-47	6.9	240
97	Ask the Expert: Schizophrenia. <i>Focus (American Psychiatric Publishing)</i> , <b>2012</b> , 10, 154-156	1.1	
96	Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nature Reviews Endocrinology</i> , <b>2011</b> , 8, 114-26	15.2	633
95	Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. <i>European Psychiatry</i> , <b>2011</b> , 26, 3-16	6	16
94	Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2011</b> , 21, 517-35	2.9	184
93	Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. <i>Schizophrenia Research</i> , <b>2011</b> , 131, 58-62	3.6	64

92	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , <b>2011</b> , 10, 138-51	14.4	489
91	Antipsychotic drugs and obesity. <i>Trends in Molecular Medicine</i> , <b>2011</b> , 17, 97-107	11.5	202
90	Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. <i>British Journal of Psychiatry</i> , <b>2011</b> , 199, 99-105	5.4	142
89	Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. <i>European Psychiatry</i> , <b>2011</b> , 26, 144-58	6	236
88	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. <i>European Neuropsychopharmacology</i> , <b>2011</b> , 21, 621-45	1.2	142
87	Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. <i>Neuropsychopharmacology</i> , <b>2011</b> , 36, 1738-46	8.7	38
86	Quantifying clinical relevance in the treatment of schizophrenia. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, B16-39	3.5	73
85	Obesity and coronary risk in patients treated with second-generation antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2011</b> , 261, 417-23	5.1	24
84	Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2011</b> , 21, 365-8	2.9	24
83	Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2245-63	4	
82	Switching among antipsychotics in everyday clinical practice: focus on ziprasidone. <i>Postgraduate Medicine</i> , <b>2011</b> , 123, 135-59	3.7	10
81	Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. <i>American Journal of Psychiatry</i> , <b>2011</b> , 168, 806-13	11.9	146
80	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , <b>2011</b> , 10, 52-77	14.4	1288
79	Experts' recommendations for treating maladaptive aggression in youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2011</b> , 21, 505-15	2.9	19
78	Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. <i>Dialogues in Clinical Neuroscience</i> , <b>2011</b> , 13, 155-72	5.7	30
77	What are we looking for in new antipsychotics?. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72 Suppl 1, 9-13	4.6	13
76	QT interval duration and dispersion in children and adolescents treated with ziprasidone. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 854-60	4.6	21
75	Sudden deaths in psychiatric patients. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 936-41	4.6	47

74	Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 1616-27	4.6	36
73	Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 655-70	4.6	89
72	Research in people with psychosis risk syndrome: a review of the current evidence and future directions. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , <b>2010</b> , 51, 390-431	7.9	136
71	10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2010</b> , 122, 356-66	6.5	58
70	Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed?. <i>Acta Psychiatrica Scandinavica</i> , <b>2010</b> , 122, 341-4	6.5	18
69	Evidence-based flying taking off: maximising the effectiveness of a novel airline user decision-making tool. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 1836-7	2.9	0
68	Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. <i>Bipolar Disorders</i> , <b>2010</b> , 12, 116-41	3.8	143
67	Past and present progress in the pharmacologic treatment of schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1115-24	4.6	161
66	Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents. <i>Evidence-Based Mental Health</i> , <b>2010</b> , 13, 54	11.1	1
65	Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 1997-2004	8.7	158
64	Comparing clinical and neurocognitive features of the schizophrenia prodrome to the bipolar prodrome. <i>Schizophrenia Research</i> , <b>2010</b> , 123, 59-63	3.6	46
63	From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. <i>European Psychiatry</i> , <b>2010</b> , 25 Suppl 2, S12-21	6	176
62	Management of physical health in patients with schizophrenia: practical recommendations. <i>European Psychiatry</i> , <b>2010</b> , 25 Suppl 2, S41-5	6	26
61	Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 1520-30	8.7	169
60	Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. <i>Schizophrenia Research</i> , <b>2010</b> , 117, 68-74	3.6	78
59	Management of antipsychotic-related weight gain. <i>Expert Review of Neurotherapeutics</i> , <b>2010</b> , 10, 1175-2009	4.0	77
58	Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. <i>Psychiatric Services</i> , <b>2010</b> , 61, 892-8	3.3	67
57	Switching and combining antipsychotics. <i>CNS Spectrums</i> , <b>2010</b> , 15, 8-11	1.8	5

56	Pharmacologic treatment of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , <b>2010</b> , 12, 345-57	5.7	67
55	Understanding schizoaffective disorder: from psychobiology to psychosocial functioning. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71 Suppl 2, 8-13	4.6	8
54	Symptomatic presentation and initial treatment for schizophrenia in children and adolescents. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, e29	4.6	4
53	Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2009</b> , 19, 563-73	2.9	41
52	Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 443-57	1.3	301
51	AACAP 2006 Research Forum--Advancing research in early-onset bipolar disorder: barriers and suggestions. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2009</b> , 19, 3-12	2.9	16
50	Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 302, 1765-73	27.4	699
49	The QTc interval and its dispersion in patients receiving two atypical antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2009</b> , 259, 23-7	5.1	19
48	Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 629-35	1.2	155
47	Frequency and correlates of inappropriate pediatric psychiatric emergency room visits. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 1164-77	4.6	40
46	A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 1348-57	4.6	99
45	Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. <i>Bipolar Disorders</i> , <b>2008</b> , 10, 788-97	3.8	120
44	Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. <i>International Review of Psychiatry</i> , <b>2008</b> , 20, 195-201	3.6	69
43	Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2008</b> , 18, 475-90	2.9	45
42	Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2008</b> , 47, 9-20	7.2	201
41	Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. <i>Australasian Psychiatry</i> , <b>2008</b> , 16, 253-62	1.7	33
40	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. <i>Focus (American Psychiatric Publishing)</i> , <b>2008</b> , 6, 368-378	1.1	5
39	Tardive dyskinesia and new antipsychotics. <i>Current Opinion in Psychiatry</i> , <b>2008</b> , 21, 151-6	4.9	278

38	Diagnosis and treatment in the early illness phase of bipolar disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2008</b> , 258 Suppl 5, 50-4	5.1	27
37	Cost of antipsychotic polypharmacy in the treatment of schizophrenia. <i>BMC Psychiatry</i> , <b>2008</b> , 8, 19	4.2	45
36	Identification of high-risk coronary heart disease patients receiving atypical antipsychotics: single low-density lipoprotein cholesterol threshold or complex national standard?. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 578-83	4.6	4
35	Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment?. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 674-5	4.6	17
34	Antipsychotic polypharmacy, Part 2: Why use 2 antipsychotics when 1 is not good enough?. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 860-1	4.6	13
33	Elevated cardiovascular risk in patients with bipolar disorder: when does it start and where does it lead?. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 1948-52	4.6	14
32	Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69 Suppl 4, 26-36	4.6	43
31	Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2007</b> , 46, 687-700	7.2	122
30	Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. <i>Schizophrenia Research</i> , <b>2007</b> , 89, 91-100	3.6	197
29	Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: missed targets and lost opportunities. <i>Schizophrenia Research</i> , <b>2007</b> , 92, 103-7	3.6	14
28	First-episode psychosis: a window of opportunity for best practices. <i>CNS Spectrums</i> , <b>2007</b> , 12, 1-12; discussion 13-4; quiz 15-6	1.8	12
27	Early identification and high-risk strategies for bipolar disorder. <i>Bipolar Disorders</i> , <b>2007</b> , 9, 324-38	3.8	85
26	Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. <i>Schizophrenia Bulletin</i> , <b>2007</b> , 33, 703-14	1.3	135
25	One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2007</b> , 17, 647-56	2.9	64
24	Acute and long-term adverse effects of antipsychotics. <i>CNS Spectrums</i> , <b>2007</b> , 12, 10-4	1.8	22
23	Balancing efficacy and safety in treatment with antipsychotics. <i>CNS Spectrums</i> , <b>2007</b> , 12, 12-20, 35	1.8	56
22	Pharmacological management of bipolar disorder in a youth with diabetes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2007</b> , 46, 1375-1379	7.2	3
21	Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68, 546-57	4.6	156

20	Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , <b>2006</b> , 15, 177-206	3.3	138
19	Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2006</b> , 45, 771-91	7.2	298
18	Real-life switching strategies with second-generation antipsychotics. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 160-1	4.6	26
17	Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 575-83	4.6	148
16	Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. <i>BMC Psychiatry</i> , <b>2005</b> , 5, 26	4.2	124
15	Prospective study of adolescents with subsyndromal psychosis: characteristics and outcome. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2005</b> , 15, 418-33	2.9	31
14	Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 1217-21	11.9	78
13	Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story?. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 1331-2	4.6	19
12	Real-life dosing with second-generation antipsychotics. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 1610-1	4.6	9
11	Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 414-25	11.9	566
10	A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2004</b> , 14, 350-8	2.9	48
9	Pharmacogenetics of antipsychotic-induced weight gain. <i>Psychopharmacology</i> , <b>2004</b> , 174, 477-89	4.7	71
8	Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. <i>Schizophrenia Research</i> , <b>2004</b> , 68, 37-48	3.6	181
7	The schizophrenia prodrome revisited: a neurodevelopmental perspective. <i>Schizophrenia Bulletin</i> , <b>2003</b> , 29, 633-51	1.3	290
6	The assessment of "prodromal schizophrenia": unresolved issues and future directions. <i>Schizophrenia Bulletin</i> , <b>2003</b> , 29, 717-28	1.3	62
5	Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 1209-22	11.9	365
4	Treatment models and designs for intervention research during the psychotic prodrome. <i>Schizophrenia Bulletin</i> , <b>2003</b> , 29, 747-56	1.3	15
3	Early prediction of antipsychotic response in schizophrenia. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 2063-5	11.9	139



2 Approaches to Treatment-Resistant Patients 540-560 1

1 Drug-drug interactions involving antipsychotics and antihypertensives. *Expert Opinion on Drug Metabolism and Toxicology*, 5:5 1